A cash-rich, newly commercial “fallen angel” in presbyopia: VIZZ’s differentiated mechanism and early traction versus a market-priced-in safety catastrophe.
Overview
LENZ Therapeutics is transitioning from development-stage to commercial-stage after FDA approval of VIZZ (aceclidine ophthalmic solution 1.44%) on July 31, 2025—positioning it as the first/only aceclidine-based presbyopia drug in a massive market (≈128M U.S. adults; ≈1.8B globally). Early launch indicators after the October 2025 rollout reportedly exceeded expectations, but the equity suffered a severe sentiment-driven collapse in December 2025 after a single FAERS retinal tear report triggered a ~26% drop and revived fears associated with pilocarpine’s Vuity. At roughly $17/share, the stock reflects deeply distressed expectations: with pro forma cash around $324M and a market cap near ~$534M, investors are assigning minimal value to VIZZ’s future cash flows. The report argues this may be an overreaction because aceclidine’s pupil-selective mechanism differs from pilocarpine’s accommodation-driven pathway that is mechanically linked to retinal traction; the adverse event occurred in a high-risk patient who lacked recommended screening. The opportunity is framed as a high-volatility “fallen angel” with a strong cash floor and potentially large upside if the safety narrative stabilizes over the next 6–12 months.